Advertisement

Blood Products and Transfusion Therapy in the ICU

  • Damon Forbes
Chapter

Abstract

Anemia and coagulopathy are common hematologic disorders in critically ill and injured patients. Anemia can cause various physiologic derangements that may contribute to significant morbidity and mortality in the intensive care unit. Treatment of these disorders frequently requires the transfusion of blood products. Although blood component therapy has become the standard approach in most ICUs, there is a role for whole blood transfusions in more austere healthcare settings and during mass casualty events. Regardless of the type of blood product used, there is potential for adverse transfusion reactions and infectious complications. Consequently, research efforts have focused on limiting exposure to unnecessary blood product transfusions, giving rise to more restrictive transfusion strategies over the last two decades. This area remains a topic of ongoing controversy and study, and it is imperative that critical care clinicians understand the risks, benefits, and indications for blood product transfusions.

Keywords

Blood component therapy Whole blood Walking blood bank Restrictive transfusion strategy Transfusion reactions 

References

  1. 1.
    Hunt BJ. Bleeding and coagulopathies in critical care. N Engl J Med. 2014;370(9):847–59.PubMedCrossRefGoogle Scholar
  2. 2.
    Hayden SJ, et al. Anemia in critical illness: insights into etiology, consequences, and management. Am J Respir Crit Care Med. 2012;185(10):1049–57.PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Vincent JL, et al. Anemia and blood transfusion in critically ill patients. JAMA. 2002;288(12):1499–507.PubMedCrossRefGoogle Scholar
  4. 4.
    Corwin HL, et al. The CRIT Study: anemia and blood transfusion in the critically ill--current clinical practice in the United States. Crit Care Med. 2004;32(1):39–52.PubMedCrossRefGoogle Scholar
  5. 5.
    Thomas J, et al. Anemia and blood transfusion practices in the critically ill: a prospective cohort review. Heart Lung. 2010;39(3):217–25.PubMedCrossRefGoogle Scholar
  6. 6.
    Levi M, Opal SM. Coagulation abnormalities in critically ill patients. Crit Care. 2006;10(4):222.PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Baughman RP, et al. Thrombocytopenia in the intensive care unit. Chest. 1993;104(4):1243–7.PubMedCrossRefGoogle Scholar
  8. 8.
    MacLeod JB, et al. Early coagulopathy predicts mortality in trauma. J Trauma. 2003;55(1):39–44.PubMedCrossRefGoogle Scholar
  9. 9.
    Rao MP, et al. Blood component use in critically ill patients. Anaesthesia. 2002;57(6):530–4.PubMedCrossRefGoogle Scholar
  10. 10.
    English SW, McIntyre L. Anemia and RBC transfusion. In: Vincent JL, et al., editors. Textbook of critical care. Philadelphia: Elsevier; 2017. p. 1188–94.Google Scholar
  11. 11.
    Nguyen BV, et al. Time course of hemoglobin concentrations in nonbleeding intensive care unit patients. Crit Care Med. 2003;31(2):406–10.PubMedCrossRefGoogle Scholar
  12. 12.
    Corwin HL, Parsonnet KC, Gettinger A. RBC transfusion in the ICU. Is there a reason? Chest. 1995;108(3):767–71.PubMedCrossRefGoogle Scholar
  13. 13.
    Roy CN. Anemia of inflammation. Hematology Am Soc Hematol Educ Program. 2010;2010:276–80.PubMedGoogle Scholar
  14. 14.
    Gangat N, Wolanskyj AP. Anemia of chronic disease. Semin Hematol. 2013;50(3):232–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Lelubre C, Vincent JL. Red blood cell transfusion in the critically ill patient. Ann Intensive Care. 2011;1:43.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Semenza GL. Regulation of oxygen homeostasis by hypoxia-inducible factor 1. Physiology (Bethesda). 2009;24:97–106.Google Scholar
  17. 17.
    Bellotto F, et al. Anemia and ischemia: myocardial injury in patients with gastrointestinal bleeding. Am J Med. 2005;118(5):548–51.PubMedCrossRefGoogle Scholar
  18. 18.
    Weiskopf RB, et al. Human cardiovascular and metabolic response to acute, severe isovolemic anemia. JAMA. 1998;279(3):217–21.PubMedCrossRefGoogle Scholar
  19. 19.
    Zollinger A, et al. Extreme hemodilution due to massive blood loss in tumor surgery. Anesthesiology. 1997;87(4):985–7.PubMedCrossRefGoogle Scholar
  20. 20.
    Leone BJ, Spahn DR. Anemia, hemodilution, and oxygen delivery. Anesth Analg. 1992;75(5):651–3.PubMedCrossRefGoogle Scholar
  21. 21.
    Gurevitz SA. Update and utilization of component therapy in blood transfusions. Lab Med. 2010;41(12):739–44.CrossRefGoogle Scholar
  22. 22.
    Allard S. Blood components and their contents. In: Thachil J, Hill QA, editors. Haematology in critical care: a practical handbook. Chichester: Wiley; 2014. p. 77–84.Google Scholar
  23. 23.
    Napolitano LM, et al. Clinical practice guideline: red blood cell transfusion in adult trauma and critical care. Crit Care Med. 2009;37(12):3124–57.PubMedCrossRefGoogle Scholar
  24. 24.
    Retter A, et al. Guidelines on the management of anaemia and red cell transfusion in adult critically ill patients. Br J Haematol. 2013;160(4):445–64.PubMedCrossRefGoogle Scholar
  25. 25.
    Beutler E, West C. The storage of hard-packed red blood cells in citrate-phosphate-dextrose (CPD) and CPD-adenine (CPDA-1). Blood. 1979;54(1):280–4.PubMedGoogle Scholar
  26. 26.
    Dzik WH, Kirkley SA. Citrate toxicity during massive blood transfusion. Transfus Med Rev. 1988;2(2):76–94.PubMedCrossRefGoogle Scholar
  27. 27.
    Buchholz DH, et al. Comparison of Adsol and CPDA-1 blood preservatives during simulated massive resuscitation after hemorrhage in swine. Transfusion. 1999;39(9):998–1004.PubMedCrossRefGoogle Scholar
  28. 28.
    Strobel E. Hemolytic transfusion reactions. Transfus Med Hemother. 2008;35(5):346–53.PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Murray NA, Roberts IA. Haemolytic disease of the newborn. Arch Dis Child Fetal Neonatal Ed. 2007;92(2):F83–8.PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Wiesen AR, et al. Equilibration of hemoglobin concentration after transfusion in medical inpatients not actively bleeding. Ann Intern Med. 1994;121(4):278–30.PubMedCrossRefGoogle Scholar
  31. 31.
    Norfolk DR. Safe transfusion – right blood, right patient, right time, and right place. In: Norfolk DR, editor. Handbook of transfusion medicine. Norwich: TSO; 2013. p. 27–40.Google Scholar
  32. 32.
    World Health Organization BTST. The clinical use of blood: handbook; 2001. [cited 2017 08/07/2017]; Available from: http://www.who.int/iris/handle/10665/42396.
  33. 33.
    Cull DL, Lally KP, Murphy KD. Compatibility of packed erythrocytes and Ringer's lactate solution. Surg Gynecol Obstet. 1991;173(1):9–12.PubMedGoogle Scholar
  34. 34.
    Albert K, et al. Ringer's lactate is compatible with the rapid infusion of AS-3 preserved packed red blood cells. Can J Anaesth. 2009;56(5):352–6.PubMedCrossRefGoogle Scholar
  35. 35.
    Han WY, Wang J. The effect of red blood cells function during autologus blood salvage using by plasmalyte A: 6AP6-4. Eur J Anaesthesiol. 2010;27(47):114–5.CrossRefGoogle Scholar
  36. 36.
    van der Meer PF. Apheresis versus whole-blood-derived platelets: pros and cons. ISBT Sci Ser. 2012;7(1):112–6.CrossRefGoogle Scholar
  37. 37.
    Green L, Allard S, Cardigan R. Modern banking, collection, compatibility testing and storage of blood and blood components. Anaesthesia. 2015;70(3):373.PubMedCrossRefGoogle Scholar
  38. 38.
    Reddoch KM, et al. Hemostatic function of apheresis platelets stored at 4 degrees C and 22 degrees C. Shock. 2014;41(Suppl 1):54–61.PubMedPubMedCentralCrossRefGoogle Scholar
  39. 39.
    Berzuini A, Spreafico M, Prati D. One size doesn’t fit all: should we reconsider the introduction of cold-stored platelets in blood bank inventories? F1000Res. 2017;6:95.PubMedPubMedCentralCrossRefGoogle Scholar
  40. 40.
    Mondoro TH, Vostal JG. Cold temperatures reduce the sensitivity of stored platelets to disaggregating agents. Platelets. 2002;13(1):11–20.PubMedCrossRefGoogle Scholar
  41. 41.
    Dunbar NM, Ornstein DL, Dumont LJ. ABO incompatible platelets: risks versus benefit. Curr Opin Hematol. 2012;19(6):475–9.PubMedCrossRefGoogle Scholar
  42. 42.
    Davenport RD, Mintz PD. Transfusion Medicine. In: McPherson RA, Pincus M, Henry JB, editors. Henry’s clinical diagnosis and management by laboratory methods. Philadelphia: Saunders Elsevier; 2007. p. 670.Google Scholar
  43. 43.
    Rebulla P. A mini-review on platelet refractoriness. Haematologica. 2005;90(2):247–53.PubMedGoogle Scholar
  44. 44.
    Hod E, Schwartz J. Platelet transfusion refractoriness. Br J Haematol. 2008;142(3):348–60.PubMedCrossRefGoogle Scholar
  45. 45.
    Pietersz RNI, Van der Meer PF. Processing and storage of blood components: strategies to improve patient safety. Int J Clin Transfus Med. 2015;3:55–64.Google Scholar
  46. 46.
    Scott E, et al. Evaluation and comparison of coagulation factor activity in fresh-frozen plasma and 24-hour plasma at thaw and after 120 hours of 1 to 6 degrees C storage. Transfusion. 2009;49(8):1584–91.PubMedCrossRefGoogle Scholar
  47. 47.
    Cardigan R, et al. Coagulation factor content of plasma produced from whole blood stored for 24 hours at ambient temperature: results from an international multicenter BEST Collaborative study. Transfusion. 2011;51(Suppl 1):50s–7s.PubMedCrossRefGoogle Scholar
  48. 48.
    Yazer MH, Cortese-Hassett A, Triulzi DJ. Coagulation factor levels in plasma frozen within 24 hours of phlebotomy over 5 days of storage at 1 to 6 degrees C. Transfusion. 2008;48(12):2525–30.PubMedCrossRefGoogle Scholar
  49. 49.
    von Heymann C, et al. Activity of clotting factors in fresh-frozen plasma during storage at 4 degrees C over 6 days. Transfusion. 2009;49(5):913–20.CrossRefGoogle Scholar
  50. 50.
    Abdel-Wahab OI, Healy B, Dzik WH. Effect of fresh-frozen plasma transfusion on prothrombin time and bleeding in patients with mild coagulation abnormalities. Transfusion. 2006;46(8):1279–85.PubMedCrossRefGoogle Scholar
  51. 51.
    O’Shaughnessy DF, et al. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol. 2004;126(1):11–28.PubMedCrossRefGoogle Scholar
  52. 52.
    Calder L, et al. Review of published recommendations and guidelines for the transfusion of allogeneic red blood cells and plasma. Can Med Assoc J. 1997;156(11 Suppl):S1–8.Google Scholar
  53. 53.
    Matijevic N, et al. Better hemostatic profiles of never-frozen liquid plasma compared with thawed fresh frozen plasma. J Trauma Acute Care Surg. 2013;74(1):84–90; discussion 90–1.PubMedCrossRefGoogle Scholar
  54. 54.
    Strumia MM, McGraw JJ. Frozen and dried plasma for civil and military use. JAMA. 1941;116(21):2378–82.CrossRefGoogle Scholar
  55. 55.
    Pusateri AE, et al. Dried plasma: state of the science and recent developments. Transfusion. 2016;56(Suppl 2):S128–39.PubMedCrossRefGoogle Scholar
  56. 56.
    Martinaud C, et al. Use of freeze-dried plasma in French intensive care unit in Afghanistan. J Trauma. 2011;71(6):1761–4; discussion 1764–5.PubMedGoogle Scholar
  57. 57.
    Bux J, Dickhorner D, Scheel E. Quality of freeze-dried (lyophilized) quarantined single-donor plasma. Transfusion. 2013;53(12):3203–9.PubMedCrossRefGoogle Scholar
  58. 58.
    Solheim BG, Chetty R, Flesland O. Indications for use and cost-effectiveness of pathogen-reduced ABO-universal plasma. Curr Opin Hematol. 2008;15(6):612–7.PubMedCrossRefGoogle Scholar
  59. 59.
    Pusateri AE, et al. Comprehensive US government program for dried plasma development. Transfusion. 2016;56(Suppl 1):S16–23.PubMedCrossRefGoogle Scholar
  60. 60.
    Starr D. Blood: an epic history of medicine and commerce. 1st ed. New York: Harper Collins; 2000.Google Scholar
  61. 61.
    Zielinski MD, et al. Back to the future: the renaissance of whole-blood transfusions for massively hemorrhaging patients. Surgery. 2014;155(5):883–6.PubMedCrossRefGoogle Scholar
  62. 62.
    Spinella PC. Warm fresh whole blood transfusion for severe hemorrhage: U.S. military and potential civilian applications. Crit Care Med. 2008;36(7 Suppl):S340–5.PubMedCrossRefGoogle Scholar
  63. 63.
    Hess JR, Thomas MJ. Blood use in war and disaster: lessons from the past century. Transfusion. 2003;43(11):1622–33.PubMedCrossRefGoogle Scholar
  64. 64.
    Moss GS, Valeri CR, Brodine CE. Clinical experience with the use of frozen blood in combat casualties. N Engl J Med. 1968;278(14):747–52.PubMedCrossRefGoogle Scholar
  65. 65.
    Goforth CW, et al. Fresh whole blood transfusion: military and civilian implications. Crit Care Nurse. 2016;36(3):50–7.PubMedCrossRefGoogle Scholar
  66. 66.
    Kaufman R. A fresh take on whole blood. Transfusion. 2011;51(2):230–3.PubMedCrossRefGoogle Scholar
  67. 67.
    Kauvar DS, et al. Fresh whole blood transfusion: a controversial military practice. J Trauma. 2006;61(1):181–4.PubMedCrossRefGoogle Scholar
  68. 68.
    Spinella PC, et al. Warm fresh whole blood is independently associated with improved survival for patients with combat-related traumatic injuries. J Trauma. 2009;66(4 Suppl):S69–76.PubMedPubMedCentralCrossRefGoogle Scholar
  69. 69.
    Murdock AD, et al. Whole blood: the future of traumatic hemorrhagic shock resuscitation. Shock. 2014;41(Suppl 1):62–9.PubMedCrossRefGoogle Scholar
  70. 70.
    Pidcoke HF, et al. Primary hemostatic capacity of whole blood: a comprehensive analysis of pathogen reduction and refrigeration effects over time. Transfusion. 2013;53(Suppl 1):137S–49S.PubMedPubMedCentralCrossRefGoogle Scholar
  71. 71.
    Repine TB, et al. The use of fresh whole blood in massive transfusion. J Trauma. 2006;60(6 Suppl):S59–69.PubMedCrossRefGoogle Scholar
  72. 72.
    Grosso SM, Keenan JO. Whole blood transfusion for exsanguinating coagulopathy in a US field surgical hospital in postwar Kosovo. J Trauma. 2000;49(1):145–8.PubMedCrossRefGoogle Scholar
  73. 73.
    Mabry RL, et al. United States Army rangers in Somalia: an analysis of combat casualties on an urban battlefield. J Trauma. 2000;49(3):515–28; discussion 528–9.PubMedCrossRefGoogle Scholar
  74. 74.
    Guideline JTTSCP. Fresh whole blood (FWB) transfusion; 2012. 10/24/2012 [cited 2017 08/08/2017]; Available from: http://www.usaisr.amedd.army.mil/cpgs/Fresh_Whole_Blood_Transfusion_24_Oct_12.pdf.
  75. 75.
    Grazzini G, Vaglio S. Red blood cell storage lesion and adverse clinical outcomes: post hoc ergo propter hoc? Blood Transfus. 2012;10(Suppl 2):s4–6.PubMedPubMedCentralGoogle Scholar
  76. 76.
    Kim-Shapiro DB, Lee J, Gladwin MT. Storage lesion: role of red blood cell breakdown. Transfusion. 2011;51(4):844–51.PubMedPubMedCentralCrossRefGoogle Scholar
  77. 77.
    Liumbruno GM, Aubuchon JP. Old blood, new blood or better stored blood? Blood Transfus. 2010;8(4):217–9.PubMedPubMedCentralGoogle Scholar
  78. 78.
    Latham JT Jr, Bove JR, Weirich FL. Chemical and hematologic changes in stored CPDA-1 blood. Transfusion. 1982;22(2):158–9.PubMedCrossRefGoogle Scholar
  79. 79.
    Golan M, et al. Transfusion of fresh whole blood stored (4 degrees C) for short period fails to improve platelet aggregation on extracellular matrix and clinical hemostasis after cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1990;99(2):354–60.PubMedGoogle Scholar
  80. 80.
    Lavee J, et al. The effect of transfusion of fresh whole blood versus platelet concentrates after cardiac operations. A scanning electron microscope study of platelet aggregation on extracellular matrix. J Thorac Cardiovasc Surg. 1989;97(2):204–12.PubMedGoogle Scholar
  81. 81.
    Hughes JD, Macdonald VW, Hess JR. Warm storage of whole blood for 72 hours. Transfusion. 2007;47(11):2050–6.PubMedCrossRefGoogle Scholar
  82. 82.
    Hrezo RJ, Clark J. The walking blood bank: an alternative blood supply in military mass casualties. Disaster Manag Response. 2003;1(1):19–22.PubMedCrossRefGoogle Scholar
  83. 83.
    Garcia Hejl C, et al. The implementation of a multinational “walking blood bank” in a combat zone: the experience of a health service team deployed to a medical treatment facility in Afghanistan. J Trauma Acute Care Surg. 2015;78(5):949–54.PubMedCrossRefGoogle Scholar
  84. 84.
    Adams RC, Lundy JS. Anesthesia in cases of poor surgical risk: some suggestions for decreasing the risk. Surg Gynecol Obstet. 1942;74:1011–101.Google Scholar
  85. 85.
    Wang JK, Klein HG. Red blood cell transfusion in the treatment and management of anaemia: the search for the elusive transfusion trigger. Vox Sang. 2010;98(1):2–11.PubMedCrossRefGoogle Scholar
  86. 86.
    Friedman BA, Burns TL, Schork MA. An analysis of blood transfusion of surgical patients by sex: a question for the transfusion trigger. Transfusion. 1980;20(2):179–88.PubMedCrossRefGoogle Scholar
  87. 87.
    Hebert PC, et al. Does transfusion practice affect mortality in critically ill patients? Transfusion Requirements in Critical Care (TRICC) Investigators and the Canadian Critical Care Trials Group. Am J Respir Crit Care Med. 1997;155(5):1618–23.PubMedCrossRefGoogle Scholar
  88. 88.
    Carson JL, et al. Effect of anaemia and cardiovascular disease on surgical mortality and morbidity. Lancet. 1996;348(9034):1055–60.PubMedCrossRefGoogle Scholar
  89. 89.
    Bordin JO, Heddle NM, Blajchman MA. Biologic effects of leukocytes present in transfused cellular blood products. Blood. 1994;84(6):1703–21.PubMedGoogle Scholar
  90. 90.
    Langenfeld JE, Livingston DH, Machiedo GW. Red cell deformability is an early indicator of infection. Surgery. 1991;110(2):398–403; discussion 403–4.PubMedGoogle Scholar
  91. 91.
    Hebert PC, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med. 1999;340(6):409–17.CrossRefPubMedGoogle Scholar
  92. 92.
    Carson JL, et al. Liberal or restrictive transfusion in high-risk patients after hip surgery. N Engl J Med. 2011;365(26):2453–62.PubMedPubMedCentralCrossRefGoogle Scholar
  93. 93.
    Villanueva C, et al. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med. 2013;368(1):11–21.PubMedCrossRefGoogle Scholar
  94. 94.
    Holst LB, et al. Lower versus higher hemoglobin threshold for transfusion in septic shock. N Engl J Med. 2014;371(15):1381–91.PubMedCrossRefGoogle Scholar
  95. 95.
    Hamm CW, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2011;32(23):2999–3054.PubMedCrossRefGoogle Scholar
  96. 96.
    Ferraris VA, et al. 2011 update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines. Ann Thorac Surg. 2011;91(3):944–82.PubMedCrossRefGoogle Scholar
  97. 97.
    Carson JL, et al. Clinical practice guidelines from the AABB: red blood cell transfusion thresholds and storage. JAMA. 2016;316(19):2025–35.PubMedCrossRefGoogle Scholar
  98. 98.
    Delaney M, et al. Transfusion reactions: prevention, diagnosis, and treatment. Lancet. 2016;388(10061):2825–36.PubMedCrossRefGoogle Scholar
  99. 99.
    Savage WJ. Transfusion reactions. Hematol Oncol Clin North Am. 2016;30(3):619–34.PubMedCrossRefGoogle Scholar
  100. 100.
    Tobian AA, King KE, Ness PM. Transfusion premedications: a growing practice not based on evidence. Transfusion. 2007;47(6):1089–96.PubMedCrossRefGoogle Scholar
  101. 101.
    Hirayama F. Current understanding of allergic transfusion reactions: incidence, pathogenesis, laboratory tests, prevention and treatment. Br J Haematol. 2013;160(4):434–44.PubMedCrossRefGoogle Scholar
  102. 102.
    Runge JW, et al. Histamine antagonists in the treatment of acute allergic reactions. Ann Emerg Med. 1992;21(3):237–42.PubMedCrossRefGoogle Scholar
  103. 103.
    Sanders RP, et al. Premedication with acetaminophen or diphenhydramine for transfusion with leucoreduced blood products in children. Br J Haematol. 2005;130(5):781–7.PubMedCrossRefGoogle Scholar
  104. 104.
    Marti-Carvajal AJ, et al. Pharmacological interventions for the prevention of allergic and febrile non-haemolytic transfusion reactions. Cochrane Database Syst Rev. 2010:Cd007539.Google Scholar
  105. 105.
    Narick C, Triulzi DJ, Yazer MH. Transfusion-associated circulatory overload after plasma transfusion. Transfusion. 2012;52(1):160–5.PubMedCrossRefGoogle Scholar
  106. 106.
    Raval JS, et al. Passive reporting greatly underestimates the rate of transfusion-associated circulatory overload after platelet transfusion. Vox Sang. 2015;108(4):387–92.PubMedCrossRefGoogle Scholar
  107. 107.
    Andrzejewski C Jr, Casey MA, Popovsky MA. How we view and approach transfusion-associated circulatory overload: pathogenesis, diagnosis, management, mitigation, and prevention. Transfusion. 2013;53(12):3037–47.PubMedCrossRefGoogle Scholar
  108. 108.
    Zhou L, et al. Use of B-natriuretic peptide as a diagnostic marker in the differential diagnosis of transfusion-associated circulatory overload. Transfusion. 2005;45(7):1056–63.PubMedCrossRefGoogle Scholar
  109. 109.
    Silliman CC, et al. Transfusion-related acute lung injury: epidemiology and a prospective analysis of etiologic factors. Blood. 2003;101(2):454–62.PubMedCrossRefGoogle Scholar
  110. 110.
    Wallis JP. Transfusion-related acute lung injury (TRALI)--under-diagnosed and under-reported. Br J Anaesth. 2003;90(5):573–6.PubMedCrossRefGoogle Scholar
  111. 111.
    Silliman CC, Ambruso DR, Boshkov LK. Transfusion-related acute lung injury. Blood. 2005;105(6):2266–73.PubMedCrossRefGoogle Scholar
  112. 112.
    Toy P, et al. Transfusion-related acute lung injury: incidence and risk factors. Blood. 2012;119(7):1757–67.PubMedPubMedCentralCrossRefGoogle Scholar
  113. 113.
    Gajic O, et al. Transfusion from male-only versus female donors in critically ill recipients of high plasma volume components. Crit Care Med. 2007;35(7):1645–8.PubMedCrossRefGoogle Scholar
  114. 114.
    Endres RO, et al. Identification of specificities of antibodies against human leukocyte antigens in blood donors. Transfusion. 2010;50(8):1749–60.PubMedPubMedCentralCrossRefGoogle Scholar
  115. 115.
    Chapman CE, et al. Ten years of hemovigilance reports of transfusion-related acute lung injury in the United Kingdom and the impact of preferential use of male donor plasma. Transfusion. 2009;49(3):440–52.PubMedCrossRefGoogle Scholar
  116. 116.
    Arora S, Singh PM, Trikha A. Ventilatory strategies in trauma patients. J Emerg Trauma Shock. 2014;7(1):25–31.PubMedPubMedCentralCrossRefGoogle Scholar
  117. 117.
    Garratty G. What do we mean by “Hyperhaemolysis” and what is the cause? Transfus Med. 2012;22(2):77–9.PubMedCrossRefGoogle Scholar
  118. 118.
    Maskens C, et al. Hospital-based transfusion error tracking from 2005 to 2010: identifying the key errors threatening patient transfusion safety. Transfusion. 2014;54(1):66–73; quiz 65.PubMedCrossRefGoogle Scholar
  119. 119.
    Dasararaju R, Marques MB. Adverse effects of transfusion. Cancer Control. 2015;22(1):16–25.PubMedCrossRefGoogle Scholar
  120. 120.
    Zantek ND, et al. The direct antiglobulin test: a critical step in the evaluation of hemolysis. Am J Hematol. 2012;87(7):707–9.PubMedCrossRefGoogle Scholar
  121. 121.
    Cho YS, Lim H, Kim SH. Comparison of lactated Ringer’s solution and 0.9% saline in the treatment of rhabdomyolysis induced by doxylamine intoxication. Emerg Med J. 2007;24(4):276–80.PubMedPubMedCentralCrossRefGoogle Scholar
  122. 122.
    Parekh R, Care DA, Tainter CR. Rhabdomyolysis: advances in diagnosis and treatment. Emerg Med Pract. 2012;14(3):1–15; quiz 15.PubMedGoogle Scholar
  123. 123.
    Whitby LEH. The hazards of transfusion. Lancet. 1942;239(6194):581–608.CrossRefGoogle Scholar
  124. 124.
    Drummond JR. Dangerous contaminants in stored blood. Lancet. 1956;271(6955):1267–8.PubMedCrossRefGoogle Scholar
  125. 125.
    Schreiber GB, et al. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med. 1996;334(26):1685–90.PubMedCrossRefGoogle Scholar
  126. 126.
    Bihl F, et al. Transfusion-transmitted infections. J Transl Med. 2007;5:25.PubMedPubMedCentralCrossRefGoogle Scholar
  127. 127.
    Hillyer CD, et al. Bacterial contamination of blood components: risks, strategies, and regulation: joint ASH and AABB educational session in transfusion medicine. Hematology Am Soc Hematol Educ Program. 2003;1:575–89.CrossRefGoogle Scholar
  128. 128.
    Fang CT, et al. Detection of bacterial contamination in apheresis platelet products: American Red Cross experience, 2004. Transfusion. 2005;45(12):1845–52.PubMedCrossRefGoogle Scholar
  129. 129.
    Funk MB, et al. Transfusion-transmitted bacterial infections – haemovigilance data of German blood establishments (1997–2010). Transfus Med Hemother. 2011;38(4):266–71.PubMedPubMedCentralCrossRefGoogle Scholar
  130. 130.
    Murphy WG, Coakley P. Testing platelet components for bacterial contamination. Transfus Apher Sci. 2011;45(1):69–74.PubMedCrossRefGoogle Scholar
  131. 131.
    Tinegate H, et al. Guideline on the investigation and management of acute transfusion reactions. Prepared by the BCSH Blood Transfusion Task Force. Br J Haematol. 2012;159(2):143–53.PubMedCrossRefGoogle Scholar
  132. 132.
    Eder AF, Goldman M. How do I investigate septic transfusion reactions and blood donors with culture-positive platelet donations? Transfusion. 2011;51(8):1662–8.PubMedCrossRefGoogle Scholar
  133. 133.
    Martin M, et al. Battlefield resuscitation of the future. In: Martin MJ, Beekley AC, Eckert MJ, editors. Front line surgery. 2nd ed. New York: Springer Publishing Inc; 2017.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Pulmonary & Critical Care ServiceWomack Army Medical CenterFt. BraggUSA

Personalised recommendations